DEVELOP LIVE ATTENUATED COLD-ADAPTED INFLUENZA VACCINE

提供甲型和B型流感病毒冷适应性疫苗 与人体内使用的相关表面抗原一起。 确定稳定、高 产生用于生产B型疫苗的供体菌株。 获得并表征A型和B型ca供体病毒的复制物 这些CA患者的单个基因。 来自田间疫苗的试验分离株 在生物标记和随后的基因型异常的试验。 提供A型和B型供体的重组DNA克隆并测序 基因. 提供使用二价和多价药物的基线数据c 在动物模型中应用于人的疫苗制剂。 这些方法旨在建立寒冷的遗传机制这些方法旨在建立寒冷的遗传机制 适应和衰减。 实现这些目标所需的努力 将按照以下指导方针以成本效益来实现目标：沿着 这些疫苗的最终许可。

Provide cold-adapted reassortant vaccines of influenza virus types A and B with the relevant surface antigens for use inman. Identify a stable, high yielding donor strain for use in producing type B reassortant vaccines. Derive and characterize reassortants of both type A and B ca donor viruses with single genes from these ca patients. Test isolatesfrom field vaccine trials for anomalies in biological markers and subsequently in genotypes. Provide and sequence recombinant DNA clones of both types A and B donor genes. Furnish baseline data from the use of bivalent and polyvalentca vaccine preparations in an animal model for application in man. The approaches are designed to establish the geneticmechanisms of cold adaptation and attenuation. The efforts necessary to achieve these objectives will be performed withcost effectiveness along guidelines for the eventual licensing of these vaccines.